Table 2. Univariate and multivariate analysis of prognostic factors for PA-induced HSOS.
| Variable | OS | ||||
|---|---|---|---|---|---|
| Univariate analysis | Multivariate analysis | ||||
| HR (95% CI) | P value | HR (95% CI) | P value | ||
| Age (<60 vs. ≥60 y) | 1.26 (0.65–2.44) | 0.50 | |||
| Sex (female vs. male) | 1.24 (0.61–2.52) | 0.56 | |||
| Leukocyte >1 ULN | 1.71 (0.60–4.91) | 0.32 | |||
| Erythrocytes <1 LLN | 1.10 (0.45–2.69) | 0.84 | |||
| Hemoglobin <1 ULN | 1.41 (0.60–3.31) | 0.43 | |||
| Platelet <1 ULN | 1.29 (0.66–2.49) | 0.46 | |||
| Total bilirubin >51.3 μmol/L | 1.79 (0.91–3.49) | 0.09 | |||
| ALT >2 ULN | 1.14 (0.59–2.18) | 0.70 | |||
| AST >2 ULN | 1.80 (0.90–3.60) | 0.10 | |||
| Serum albumin <35 g/L | 2.33 (0.90–6.02) | 0.08 | 3.58 (1.06–12.10) | 0.04 | |
| INR >1 ULN | 3.31 (1.50–7.31) | <0.01 | |||
| PT >1 ULN | 3.90 (1.62–9.40) | <0.01 | |||
| Serum creatinine >1.2 ULN | 1.55 (0.47–5.07) | 0.47 | |||
| Urea >1 ULN | 2.55 (1.18–5.50) | 0.02 | 2.81 (1.25–6.33) | 0.01 | |
| FIB-4 score >3.25 | 3.78 (0.90–15.84) | 0.07 | |||
| APRI score >2 | 1.33 (0.66–2.69) | 0.43 | |||
| MELD score >14 | 3.08 (1.49–6.35) | <0.01 | |||
| Grade (mild, moderate vs. severe, very severe)† | 3.10 (1.58–6.06) | <0.01 | 2.24 (1.00–5.06) | 0.05 | |
| Child-Pugh class (A vs. B, C) | 4.21 (1.01–17.55) | <0.05 | |||
HR and relative P values were estimated by Cox proportional hazard regression analysis. †, refers to the new criteria for severity grading of HSCT-related HSOS in adults (19). PA, pyrrolizidine alkaloid; HSOS, hepatic sinusoidal obstruction syndrome; OS, overall survival; HR, hazard ratio; CI, confidence interval; ULN, upper limit of normal; LLN, lower limits of normal; APRI, AST-to Platelet Ratio; FIB-4, Fibrosis 4 Score; MELD, model for end-stage liver disease.